Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen, Inc. (NASDAQ: OCGN) will have its CEO, Dr. Shankar Musunuri, speak at Xconomy’s virtual event on December 3, 2020, discussing cell and gene therapies. The panel, moderated by Theresa Lavoie, will cover regulatory and reimbursement roadblocks facing the industry. Ocugen aims to develop transformative therapies for blindness diseases, utilizing a modifier gene therapy platform that treats multiple retinal diseases efficiently. Investors may find interest in the company's innovative approaches as they seek to address underserved diseases.
Ocugen, Inc. (NASDAQ: OCGN) reported its third quarter 2020 results, highlighting progress in its gene therapy developments.
The company is on track to initiate four Phase 1/2a trials in 2021-2022, specifically for its lead candidate OCU400. Ocugen raised approximately $28 million in 2020, enhancing its financial position.
As of September 30, 2020, cash reserves were $19.3 million, a significant increase from $7.6 million at year-end 2019. The company incurred a loss of $0.07 per share, markedly improving from a $3.55 loss per share in 2019.
Ocugen (NASDAQ: OCGN) will present at the Global Chinese Financial Forum Virtual Conference on November 5 at 1:45 PM ET. Dr. Shankar Musunuri, CEO, will discuss the company's innovative modifier gene therapy platform and lead product candidate, OCU400, which targets broad Retinitis Pigmentosa with four FDA orphan drug designations. The presentation will also cover Ocugen's partnership with CanSino Biologics for OCU400 in Greater China and the preclinical development of OCU200 for sight-threatening diseases. Registration for the conference is free.
Ocugen, Inc. (NASDAQ: OCGN) announced that Dr. Shankar Musunuri, CEO and Co-Founder, will present on strategic partnerships in gene therapy at the 4th Annual Gene Therapy for Rare Disorders Europe Conference from October 26-28, 2020. His presentation, titled “The Importance of Strategic Partnerships in Gene Therapy,” is scheduled for October 28 at 11:00 AM GMT. Ocugen focuses on transformative therapies for blindness, leveraging its modifier gene therapy platform to address multiple retinal diseases.
Ocugen, Inc. (NASDAQ: OCGN) announced a Management Fireside Chat on October 21, 2020, at 11 a.m. ET, hosted by Cantor Fitzgerald. The discussion will feature key management figures, including Dr. Shankar Musunuri and Sanjay Subramanian, focusing on their lead program OCU400 for retinal degeneration disorders. The management will share clinical outcomes published in Nature Gene Therapy and updates on upcoming clinical trials. Cantor Fitzgerald has initiated coverage of Ocugen with an 'Overweight' rating and a $1.00 price target, highlighting the potential of AAV-based gene therapies.
Ocugen has announced an agreement with Kemwell Biopharma to manufacture OCU200, its biologic candidate for treating severe sight-threatening diseases. The collaboration aims to ensure product consistency for IND-enabling toxicology studies and Phase 1/2a clinical trials, targeting a clinic entry by 1H 2022. OCU200 addresses retinal diseases affecting over 9.5 million U.S. patients, with a unique mechanism compared to traditional therapies. This partnership is expected to facilitate the development of new treatments for patients who do not respond to existing therapies.
Ocugen, a biopharmaceutical company, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21, 2020, at 1:40 PM ET. Dr. Shankar Musunuri, CEO, will discuss the company’s innovative gene therapy platform and its lead product candidate, OCU400, aimed at treating retinitis pigmentosa. OCU400 recently received its fourth FDA orphan drug designation. The conference runs from September 21-23. For more details, visit www.ocugen.com.
Ocugen (NASDAQ: OCGN) announced it has been granted an additional 180-day compliance period by Nasdaq to meet the minimum bid price of $1.00 per share. This extension lasts until March 8, 2021, after the company failed to comply during the initial grace period. If the company's stock price closes at or above $1.00 for 10 consecutive days within this timeframe, compliance will be regained. Should it fail again, Ocugen may face delisting, although it can appeal the decision. The current notice does not affect the stock's trading status.
Ocugen (NASDAQ: OCGN) announced its participation in the LD 500 Virtual Investor Conference on September 4, 2020, at 11 a.m. ET. CFO Sanjay Subramanian will discuss the company's breakthrough gene therapy platform and lead product candidate, OCU400, designed to treat various forms of retinitis pigmentosa. This candidate has recently received its fourth FDA orphan drug designation. The conference runs from September 1-4, featuring key players from the micro-cap sector.
Ocugen, Inc. (NASDAQ: OCGN) reported its Q2 2020 financial results, highlighting significant advancements in its gene therapy pipeline aimed at curing blindness. The company received two additional Orphan Drug Designations for its OCU400 program, making a total of four ODDs to target specific retinal degenerations. Despite the ongoing pandemic, Ocugen is on track to enter clinical trials next year. The company secured $15.4 million in funding, increasing its cash runway, although it reported a net loss of $3.6 million for the quarter, compared to a loss of $3.5 million in Q2 2019.